GridAI Technologies Corp.
GRDXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, GridAI Technologies Corp. (GRDX) is listed under Biotechnology. With a market capitalization of $22.8M, it sits in micro-cap territory. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency.
Market Cap
$22.8M
Beta
—
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-6.39
EPS (Fwd)
—
ROE
—
ROA
—
Cash
—
Total Debt
—
Free CF
—
52W Change
31.1%
Annual Financials
Cash vs Debt
Where GRDX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, GRDX finished 2.37% above its 150-day moving average ($3.38) and 3.28% above its 200-day moving average ($3.35). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GRDX overbought or oversold?
At the September 3, 2026 close, GRDX's RSI(14) was 42.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Investors considering GridAI Technologies Corp. should weigh the typical risks associated with GRDX's sector, size, and financial profile against their own risk tolerance and investment objectives. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence GridAI Technologies Corp.'s trajectory.